272 related articles for article (PubMed ID: 7520906)
1. Extrapyramidal side effects and tolerability of risperidone: a review.
Owens DG
J Clin Psychiatry; 1994 May; 55 Suppl():29-35. PubMed ID: 7520906
[TBL] [Abstract][Full Text] [Related]
2. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Keegan D
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
[TBL] [Abstract][Full Text] [Related]
6. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Fleischhacker WW; Lemmens P; van Baelen B
Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
[TBL] [Abstract][Full Text] [Related]
7. Risperidone: clinical safety and efficacy in schizophrenia.
Borison RL; Pathiraja AP; Diamond BI; Meibach RC
Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
[TBL] [Abstract][Full Text] [Related]
8. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
[TBL] [Abstract][Full Text] [Related]
9. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
10. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Timdahl K; Carlsson A; Stening G
Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Kim JH; Byun HJ
J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
[TBL] [Abstract][Full Text] [Related]
14. Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Schooler NR
J Clin Psychiatry; 1994 May; 55 Suppl():22-8. PubMed ID: 7520905
[TBL] [Abstract][Full Text] [Related]
15. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Cesková E; Svestka J
Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
[TBL] [Abstract][Full Text] [Related]
18. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Kopala LC; Honer WG
J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
[No Abstract] [Full Text] [Related]
19. Clinical review of risperidone.
Chouinard G; Arnott W
Can J Psychiatry; 1993 Sep; 38 Suppl 3():S89-95. PubMed ID: 7504574
[TBL] [Abstract][Full Text] [Related]
20. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
